Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability.

Saved in:
Bibliographic Details
Title: Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability.
Authors: Huttner A; Division of Infectious Diseases, University Hospitals of Geneva, Geneva, Switzerland; Clinical Trials Unit, Centre for Clinical Research, University Hospitals of Geneva and Faculty of Medicine, Geneva, Switzerland; Centre for Vaccinology, University Hospitals of Geneva and Faculty of Medicine, Geneva, Switzerland. Electronic address: Angela.huttner@hcuge.ch., Agnandji ST; Centre de Recherches Médicales de Lambaréné, Campus CERMEL, Lambaréné, Gabon; Institut für Tropenmedizin, Reisemedizin und Humanparasitologie Universitätsklinikum Tübingen, Tübingen, Germany; GermanCenter for Infection Research (DZIF), Partner Site Tübingen, Tübingen, Germany., Engler O; Spiez Laboratory, Federal Office for Civil Protection, Spiez, Switzerland., Hooper JW; Foundational Science Directorate, US Army Medical Research Institute of Infectious Diseases, Frederick, MD, USA., Kwilas S; Foundational Science Directorate, US Army Medical Research Institute of Infectious Diseases, Frederick, MD, USA., Ricks K; Foundational Science Directorate, US Army Medical Research Institute of Infectious Diseases, Frederick, MD, USA., Clements TL; Foundational Science Directorate, US Army Medical Research Institute of Infectious Diseases, Frederick, MD, USA., Jonsdottir HR; Spiez Laboratory, Federal Office for Civil Protection, Spiez, Switzerland., Nakka SS; Department of Microbiology and Immunology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Rothenberger S; Spiez Laboratory, Federal Office for Civil Protection, Spiez, Switzerland; Institute of Microbiology, University Hospital Center and University of Lausanne, Lausanne, Switzerland., Kremsner P; Centre de Recherches Médicales de Lambaréné, Campus CERMEL, Lambaréné, Gabon; Institut für Tropenmedizin, Reisemedizin und Humanparasitologie Universitätsklinikum Tübingen, Tübingen, Germany; GermanCenter for Infection Research (DZIF), Partner Site Tübingen, Tübingen, Germany., Züst R; Spiez Laboratory, Federal Office for Civil Protection, Spiez, Switzerland., Medaglini D; Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy., Ottenhoff T; Department of Infectious Diseases, Leiden Hospital Centre and University Hospital, Leiden, The Netherlands., Harandi AM; Department of Microbiology and Immunology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Vaccine Evaluation Centre, BC Children's Hospital Research Institute, University of British Columbia, Vancouver, BC, Canada., Siegrist CA; Centre for Vaccinology, University Hospitals of Geneva and Faculty of Medicine, Geneva, Switzerland.
Corporate Authors: VEBCON, VSV-EBOVAC, VSV-EBOPLUS Consortia
Source: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases [Clin Microbiol Infect] 2023 Dec; Vol. 29 (12), pp. 1587-1594. Date of Electronic Publication: 2023 Sep 03.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9516420 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1469-0691 (Electronic) Linking ISSN: 1198743X NLM ISO Abbreviation: Clin Microbiol Infect Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1469-0691
DOI:10.1016/j.cmi.2023.08.026